Your Weekly Biotech News Fix | Ep. 1041
The week of 7.20.2026
Hello Avatar! Another week of biotech news is in the history books. We are proud to bring you the latest edition of our weekly biotech news fix. The content is designed to be consumed as a quick scroll to bring readers up to speed on key events from the week. For those of you interested to read a bit more, we provide links to the source articles.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
Weekly Biotech Summary
Week of July 20, 2026
This week in biotech saw significant regulatory, clinical, and financial developments. Sanofi halted development of a once-promising immune drug, while GSK secured an early FDA approval following its major Nuvalent acquisition. Scribe Therapeutics broke a two-year drought for gene editing IPOs, and Summit Therapeutics faces a cash crunch as it awaits a pivotal FDA decision. Policy and M&A activity also made headlines, including potential tariffs on generic drugs, a major cell therapy supply acquisition, and a high-profile FDA panel vote on peptides.
Market Snapshot
For the week, the public indexes were MIXED, with the S&P -0.4% & DOW moving +0.2%. For the year both remain UP +8.1% and +7.4% respectively. The XBI (the biotech index) comes in DOWN -0.3% for the week and remains +24.0% for the year.
Clinical Data
Sanofi ends pursuit of amlitelimab for eczema after mixed results and safety concerns
What happened
Sanofi has decided to discontinue the development of amlitelimab for atopic dermatitis (eczema) following inconsistent late-stage trial results and safety issues, including cases of Kaposi’s sarcoma. The drug, acquired through Sanofi’s $1.1 billion purchase of Kymab in 2021, had been seen as a potential blockbuster but failed to meet expectations in efficacy and safety. This move follows similar setbacks for other OX40L-targeting antibodies in the industry.
Why it matters
The decision marks a significant pipeline setback for Sanofi and raises questions about its future R&D strategy. It may prompt the company to seek new assets through partnerships or acquisitions to offset the loss and maintain long-term revenue growth.
Financing/IPO
Scribe Therapeutics raises $129M in first gene editing IPO in over two years
What happened
Scribe Therapeutics secured nearly $129 million in its initial public offering, the first gene editing biotech to go public in more than two years. The California-based company will use the proceeds to advance its lead asset, STX-1150, an epigenetic silencing therapy for atherosclerotic cardiovascular disease, which recently entered human testing. Scribe has also entered licensing deals with Sanofi and Eli Lilly.
Why it matters
This IPO signals renewed investor interest in early-stage biotech and gene editing platforms, despite a recent preference for de-risked clinical programs. Scribe’s successful raise could encourage other early-stage biotechs to consider public offerings.
Regulatory/M&A
GSK wins FDA approval for lung cancer drug after Nuvalent acquisition
What happened
GSK received FDA approval for zidesamtinib (Jideytro), a ROS1 inhibitor for advanced non-small cell lung cancer, shortly after acquiring Nuvalent Bio for $10.6 billion. The approval was supported by positive Phase 1/2 trial data and marks GSK’s entry into the lung cancer market. The deal also brought additional NSCLC assets into GSK’s pipeline.
Why it matters
The rapid regulatory win validates GSK’s acquisition strategy and strengthens its oncology portfolio. It demonstrates the value of targeted M&A in accelerating market entry and could influence future dealmaking in the sector.
Clinical/Financial
Summit Therapeutics faces cash shortfall as FDA decision on key cancer drug approaches
What happened
Summit Therapeutics reported that its current cash reserves are insufficient to fund operations for another year, as it awaits an FDA decision on its PD-1/VEGF bispecific antibody, ivonescimab, for advanced non-small cell lung cancer. Recent data showed a 24% decrease in overall risk of death with the drug, but questions remain about efficacy in Western patients.
Why it matters
The company’s financial position heightens the stakes of the upcoming FDA verdict. A positive decision could provide a lifeline, while a negative outcome may force Summit to seek additional funding or strategic alternatives.
M&A
Lilly’s $3.8B acquisition in psychedelics unlikely to spark widespread M&A
What happened
Eli Lilly announced a $3.8 billion acquisition of AtaiBeckley, a developer of psychedelic therapies, marking a major endorsement of the drug class. However, analysts suggest this move is unlikely to trigger a wave of similar deals, citing a limited pool of targets and the need for more clinical and regulatory clarity before broader industry adoption.
Why it matters
While the deal validates the potential of psychedelics in neuropsychiatric treatment, it is not expected to immediately reshape the M&A landscape. Investors and companies will likely wait for further evidence of market viability before committing to additional large-scale deals.
Clinical Data
Arrowhead’s plozasiran shows strong Phase 3 results in lowering triglycerides and pancreatitis risk
What happened
Arrowhead Pharmaceuticals reported positive Phase 3 trial results for plozasiran, an RNA-based therapy for severe hypertriglyceridemia. The drug reduced median triglyceride levels by up to 81% and lowered acute pancreatitis events by 78% compared to placebo, with a favorable safety profile. Arrowhead plans to seek label expansion later this year.
Why it matters
These results position plozasiran as a strong competitor to existing therapies, potentially capturing significant market share. The data also support the broader adoption of RNA-based medicines for metabolic diseases.
Policy/Market Risk
Potential tariffs on imported generics raise concerns for drug supply and pricing
What happened
The prospect of tariffs up to 200% on imported generic drugs has raised alarms among manufacturers and investors. While previous tariffs on branded drugs had limited impact, generics operate on thin margins, and new levies could lead to product discontinuations, shortages, or quality concerns. The industry is seeking clarity on the proposed policy.
Why it matters
Tariffs on generics could disrupt supply chains and increase costs for patients and healthcare systems. The uncertainty adds risk for generic drugmakers and could affect the availability of affordable medicines in the U.S.
Regulatory
Amgen mounts defense of Tavneos as FDA considers market withdrawal
What happened
Amgen has requested a hearing with the FDA to contest the proposed withdrawal of Tavneos, a rare disease drug for ANCA-associated vasculitis, due to liver toxicity concerns and reported deaths. The company submitted new data and patient testimonials to support the drug’s benefit-risk profile, arguing for its continued availability.
Why it matters
The outcome will impact Amgen’s rare disease portfolio and could set precedents for regulatory actions on drugs with safety concerns in rare indications. It also highlights the challenges of balancing patient need with safety in rare disease drug approvals.
M&A
Repligen acquires BioLife Solutions for $1.5B to expand cell therapy supply capabilities
What happened
Repligen announced a $1.5 billion acquisition of BioLife Solutions, a key supplier of cryopreservation media used in commercial and late-stage cell therapies. The deal is expected to strengthen Repligen’s position in the cell therapy supply chain and generate cost and revenue synergies.
Why it matters
This acquisition enhances Repligen’s role in the growing cell therapy market and may influence supply chain strategies for leading cell therapy developers. It also reflects ongoing consolidation in the bioprocessing and CDMO sectors.
Regulatory
FDA panel narrowly backs broader use of peptides despite limited evidence
What happened
An FDA advisory panel narrowly recommended expanding the use of four peptides, despite limited evidence of efficacy and safety. The meeting was marked by conflicts of interest and concerns about political influence, with divided opinions among panelists and FDA staff.
Why it matters
The endorsement could open new markets for peptide therapies but raises questions about regulatory standards and patient safety. The decision may prompt further scrutiny of FDA advisory processes and the evidence required for broader therapeutic use.
CONCLUSION
There you have it, another week of your Weekly Biotech News Fix. We hope you enjoyed it, please drop a comment with any feedback you may have.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
SUBSCRIBE TO PODCAST HERE:
Sundays and Mondays are under the paid umbrella, everything else is FREE. It is $11.99/month and we encourage you to support our efforts. It keeps us motivated to keep producing the hybrid science and business biotech focused content you will not find anywhere else all in the same place.
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS